AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Amgen announced new Phase 3 VESALIUS-CV data showing Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke. The trial of more than 12,000 patients demonstrated that Repatha is the first PCSK9 inhibitor to lower both all-cause and cardiovascular mortality in this primary prevention population.
Key figures
- Drug Name
- Repatha (evolocumab)
- Phase Of Trial
- Phase 3
- Patients enrolled
- 12000
- Mortality reduction
- 20%
- Median follow up years
- 4.6
- Ldl c reduction mg dl placebo
- 109
- Ldl c reduction mg dl treatment
- 45
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.